Interestingly, Dr. Bolli’s group, using a molecular genetic approach and a model of MI, has demonstrated that the cardioprotection afforded by NOS2 gene therapy is mediated by COX2 up-regulation via NFkB activation [55]. Here, NOS2 is linked to myocardial infarction.